New autoantigens in the antiphospholipid syndrome

Alessandri, Cristiano; Conti, Fabrizio; Pendolino, Monica; Mancini, Riccardo; Valesini, Guido

doi:10.1016/j.autrev.2011.04.011

Cited by 69 publications

(35 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several authors have suggested that testing for new aPL specificities may help to more clearly identify the syndrome in patients with thrombosis or pregnancy loss in whom APS is strongly suspected, but conventional aPL testing is repeatedly negative 13,14,15 . In our present study, using a highly characterized cohort of consecutive patients at St. Thomas' Hospital, London (a specialized tertiary-care center), we have evaluated a group of SN-APS patients with a series of "non-criteria" serological assays.…”

Section: Rheumatologymentioning

confidence: 99%

Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of “Non-criteria” Antiphospholipid Antibodies

Zohoury

Bertolaccini²,

Rodríguez-García³

et al. 2017

J Rheumatol

View full text Add to dashboard Cite

Objective.Most clinicians use the 2006 Sydney classification criteria to evaluate patients suspected of having antiphospholipid syndrome (APS). Although sensitive and specific for APS, many patients fulfilling clinical criteria for the syndrome are persistently negative for the specific serological tests (“laboratory criteria”). These “seronegative APS” (SN-APS) patients can go undiagnosed and untreated until they experience serious clinical events. This study’s objective was to describe antibody profiles of SN-APS patients using non-criteria markers, assess the clinical utility of these markers separately and in combination, and suggest incorporation into guidelines for patients suspected of APS.Methods.We categorized 175 consecutive patients suspected of APS into 2 subgroups: 107 fulfilling Sydney APS classification for seropositive APS (SP-APS) and 68 with clinical manifestations suggestive of APS but having negative serology, on 2 occasions, for criteria markers (SN-APS). On study inclusion, samples were retested for criteria and 11 non-criteria markers, including antiphosphatidylserine/prothrombin antibodies.Results.Using 4 of 11 non-criteria tests, a cumulative 30.9% of SN-APS patients were detected. Combining results of all 11 non-criteria tests, 25 SN-APS (36.8%) and 89 SP-APS (83.2%) were positive for 1 or more non-criteria antibodies.Conclusion.Failure to diagnose APS can result in severe clinical consequences. Patients displaying clinical features of APS, but negative for conventional criteria markers, should undergo additional testing for non-criteria biomarkers. In our cohort, around one-third of SN-APS patients showed reactivity to 1 or more non-criteria markers. An update to the current classification criteria incorporating new serological markers should be considered to identify and stratify patients with APS for more effective treatment and management.

show abstract

Section: Rheumatologymentioning

confidence: 99%

Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of “Non-criteria” Antiphospholipid Antibodies

Zohoury

Bertolaccini²,

Rodríguez-García³

et al. 2017

J Rheumatol

View full text Add to dashboard Cite

show abstract

“…The most common antibodies detected in APL are anti-cardiolipin [103] and anti-b2 Glycoprotein-1 [104]. The European registry followed babies born to mothers with anti-phospholipid antibodies and identified 138 mothers and 141 babies.…”

Section: Neonatal Anti-phospholipid Syndromementioning

confidence: 99%

Neonatal autoimmune diseases: A critical review

Chang

2012

Journal of Autoimmunity

View full text Add to dashboard Cite

“…Among diverse clinical and laboratory manifestations of APS there are also those not included in classification criteria: heart valve changes, livedo reticularis, skin ulcerations, thrombocytopenia, nephropathy, cognitive dysfunction, migraine, epilepsy, aCL antibodies of IgA isotype, anti-β 2 GPI antibodies of IgA isotype, anti-phosphatidylserin (aPS) antibodies, anti-phosphatidiletanolamin (aPE) antibodies, anti-thrombin antibodies (aPT), antibodies to complex phosphatidylserin-prothrombin (aPS/PT), anti-anexin 5 antibodies [23][24][25][26][27][28]. Including these manifestations in classification criteria would decrease diagnostic specificity for APS, but the question remains when they should be considered in diagnosis establishment [1].…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Plavšić¹,

Mišković²,

Rašković

et al. 2014

Open Access Maced J Med Sci

View full text Add to dashboard Cite

Antiphospholipid syndrome is an autoimmune disorder defined as association of vascular thrombosis and/or pregnancy complications with presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin and anti-β2 glycoprotein I). It is the most common cause of acquired thrombophilia, and can occur as an independent entity or in relation with other diseases, especially systemic lupus erythematosus. Presence of antiphospholipid syndrome in systemic lupus erythematosus is additional vaso occlusive factor in already present inflammation, bringing further risk for thrombotic events. Clinical and serological manifestations of antiphospholipid syndrome and systemic lupus erythematosus are very similar, so possible connection for these two autoimmune disorders is assumed.

show abstract

New autoantigens in the antiphospholipid syndrome

Cited by 69 publications

References 121 publications

Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of “Non-criteria” Antiphospholipid Antibodies

Closing the Serological Gap in the Antiphospholipid Syndrome: The Value of “Non-criteria” Antiphospholipid Antibodies

Neonatal autoimmune diseases: A critical review

Systemic Lupus Erythematosus and Antiphospholipid Syndrome

Contact Info

Product

Resources

About